NextDocs Corporation Expands Its Operations to Europe
Provides Microsoft Office SharePoint Server-Based Document and Quality Management Solutions for Life Sciences Industry
Munich, Germany -- NextDocs Corporation <http://www.nextdocs.com/> , a leading provider of Microsoft Office SharePoint Server-based regulatory document and quality management software, announced today that is has opened a branch office in Germany. NextDocs' line of fully FDA 21 CFR Part 11 compliant SharePoint Server-based document and quality management solutions has been developed specifically for life sciences companies to enhance productivity and reduce risk.
The new office, located in Munich, will provide local sales and technical support for the European customer base. The European subsidiary will play a vital role in the global expansion of NextDocs and enable rapid growth in the European market.
"Because our main customers are based in Central Europe, the establishment of a NextDocs presence in Munich will allow us to continue our phenomenal momentum. It is a tremendous growth opportunity for our company, and it is only the first step of our fast-growing expansion in Europe. Our intention is to provide our European customer and partners with the best available local support," said NextDocs Chief Executive Officer Zikria Syed.
Rainer Schwarz has been named NextDoc's General Manager and Sales Director for the European operation.
"I am very glad to be part of NextDocs," Mr. Schwarz said. "As NextDocs moves to the next level of corporate development, the opening of this first office in Europe is an important step for our company. The demand in the life sciences market for SharePoint Server-based content management solutions continues to be enormous. Thanks to our enhanced presence on the continent, we can focus our activities in the European time zone, provide first class support and work more closely with our customers."
The European office is located in Elisabethstrasse 91, 80797 Munich, Germany.
Tel: +49 (0) 89 5908-1210 and Fax: +49 (0) 89 5908-1200
"NextDocs Document and Quality Management suite provides a comprehensive solution based on Microsoft Office SharePoint Server that allows our life sciences customers to take full advantage of their existing Microsoft technology investments, while solving key business problems," said Ruediger Dorn, Managing Director, Worldwide Pharmaceutical Industry, Microsoft Corporation. "We are happy to partner with NextDocs to roll these solutions to the European pharmaceutical community."
About NextDocs
NextDocs is a leading provider of fully FDA 21 CFR Part 11 compliant Microsoft Office SharePoint Server-based document and quality management solutions for the life sciences companies. Our mission is to deliver cost-effective, easy-to-use document management software that provides immediate productivity increases for companies operating in regulatory environments. NextDocs customers include pharmaceutical companies, bio-techs, medical device companies and CROs. For more information please visit www.nextdocs.com <http://www.nextdocs.com/> or email information@nextdocs.com.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.